A Study of BBI503 in Advanced Solid Tumors, or BBI503/ Sorafenib in Advanced Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2018-10-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, phase 1 dose escalation study of BBI503 monotherapy, or
BBI503 in combination with Sorafenib. This study population is adult patients with advanced
solid tumors in monotherapy, or adult patients with advanced hepatocellular carcinoma in
combination therapy.